The challenge of HLA donor specific ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.
Auteur(s) :
Maanaoui, Mehdi [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Chetboun, Mikael [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Top, Isabelle [Auteur]
Institut d'Immunologie [CHRU Lille]
Elsermans, Vincent [Auteur]
Institut d'Immunologie [CHRU Lille]
Pattou KERR-CONTE, Julie [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Le Mapihan, Kristell [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Defrance, Frederique [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Gmyr, Valery [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Hubert, Thomas [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Labalette, Myriam [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hazzan, Marc [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Pattou, Francois [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Recherche translationnelle sur le diabète - U 1190 [RTD]
Chetboun, Mikael [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Top, Isabelle [Auteur]
Institut d'Immunologie [CHRU Lille]
Elsermans, Vincent [Auteur]
Institut d'Immunologie [CHRU Lille]
Pattou KERR-CONTE, Julie [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Le Mapihan, Kristell [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Defrance, Frederique [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Gmyr, Valery [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Hubert, Thomas [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Labalette, Myriam [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hazzan, Marc [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Pattou, Francois [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Titre de la revue :
Scientific Reports
Nom court de la revue :
Sci Rep
Numéro :
12
Pagination :
12463
Date de publication :
2022-07-24
ISSN :
2045-2322
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several ...
Lire la suite >Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several donor islets, which adds complexity to the analysis of their impact. Adult patients with type 1 diabetes transplanted with pancreatic islets between 2005 and 2018 were included in a single-center observational study. Thirty-two recipients with available sera tested by solid-phase assays for anti-HLA antibodies during their whole follow-up were analyzed. Twenty-five recipients were islet-transplantation-alone recipients, and 7 islet-after-kidney recipients. Seven recipients presented with DSA at any time during follow-up (two with preformed DSA only, one with preformed and de novo DSA, 4 with de novo DSA only). Only islet-transplantation-alone recipients presented with de novo DSA. Three clinical trajectories were identified according to: 1/the presence of preformed DSA, 2/early de novo DSA or 3/late de novo DSA. Only late de novo DSA were associated with unfavorable outcomes, depicted by a decrease of the β-score. Islet transplantation with preformed DSA, even with high MFI values, is associated with favorable outcomes in our experience. On the contrary, de novo DSA, and especially late de novo DSA, may be associated with allograft loss.Lire moins >
Lire la suite >Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several donor islets, which adds complexity to the analysis of their impact. Adult patients with type 1 diabetes transplanted with pancreatic islets between 2005 and 2018 were included in a single-center observational study. Thirty-two recipients with available sera tested by solid-phase assays for anti-HLA antibodies during their whole follow-up were analyzed. Twenty-five recipients were islet-transplantation-alone recipients, and 7 islet-after-kidney recipients. Seven recipients presented with DSA at any time during follow-up (two with preformed DSA only, one with preformed and de novo DSA, 4 with de novo DSA only). Only islet-transplantation-alone recipients presented with de novo DSA. Three clinical trajectories were identified according to: 1/the presence of preformed DSA, 2/early de novo DSA or 3/late de novo DSA. Only late de novo DSA were associated with unfavorable outcomes, depicted by a decrease of the β-score. Islet transplantation with preformed DSA, even with high MFI values, is associated with favorable outcomes in our experience. On the contrary, de novo DSA, and especially late de novo DSA, may be associated with allograft loss.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2024-01-12T01:01:27Z
2024-01-26T09:30:03Z
2024-01-26T09:30:03Z
Fichiers
- s41598-022-16782-3.pdf
- Non spécifié
- Accès libre
- Accéder au document